[Surfactant treatment of newborn infants with respiratory distress syndrome primarily treated with nasal continuous positive air pressure. A pilot study]

Ugeskr Laeger. 1992 Jul 27;154(31):2136-9.
[Article in Danish]


In this pilot study, Curosurf (200 mg/kg) was administrated to 34 patients with the respiratory distress syndrome in nasal-CPAP therapy with FiO2 requirements greater than 0.60 and/or TcPCO2 greater than 8 kPa. The surfactant was instilled during a short period of intubation or in a few cases via an intratracheal catheter (Ch. 6). The age of the patients on surfactant treatment ranged from two to 72 hours. Eighteen patients could be maintained on nasal-CPAP after treatment with Curosurf and only a few complications were seen in these infants. The other 16 patients subsequently required artificial ventilation and had a higher incidence of pulmonary and extrapulmonary complications. On the basis of these observations, we plan a randomized trial to investigate whether, administration of surfactant reduces the need for ventilator treatment and improves the odds for uneventful recovery in this category of patients.

Publication types

  • Clinical Trial
  • English Abstract
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Products*
  • Denmark
  • Humans
  • Infant, Newborn
  • Phospholipids*
  • Pilot Projects
  • Positive-Pressure Respiration*
  • Pulmonary Surfactants / administration & dosage*
  • Respiratory Distress Syndrome, Newborn / diagnosis
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Respiratory Distress Syndrome, Newborn / therapy


  • Biological Products
  • Phospholipids
  • Pulmonary Surfactants
  • poractant alfa